Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Groups Tag-Team To Attack Device Tax

This article was originally published in The Gray Sheet

Executive Summary

AdvaMed and MDMA simultaneously released survey results from their member companies arguing the tax has hurt jobs and investment in the industry and will continue to do so if it is not repealed.

You may also be interested in...



Lobbyists Again Coordinate Device Tax Attack

AdvaMed and MDMA, two rivaling lobby groups, have again come together against a common enemy: the Obamacare medical device excise tax. The groups simultaneously released survey results that argue that permanently repealing the tax would be a boon for their member companies and innovation.

Large Device Firms Thrive, Smaller Ones Dive, Post-Device Tax, GAO Says

Large device firms have thrived since the Affordable Care Act implementation applied a 2.3 percent excise tax to their sales, but medium- and small-size firms did less well, says a July 30 General Accountability Office report. But GAO did not draw a causal link between ACA, the tax, and profits.

House Votes To Repeal Device Tax, Again

Congressional leaders have again voted to repeal the 2.3 percent medical device tax criticized by industry for stifling innovation and jobs, and sent it to the Senate for approval. Concerns still surround whether the bill is approvable without an offset.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT034453

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel